5 Reasons To Buy Astex Pharmaceuticals

By Brian L. Wilson:Shares of Astex Pharmaceuticals (ASTX), the drug discovery company formed by the acquisition of Astex Therapeutics Ltd by Supergen Inc. In 2011 have been on the move.

By Matt Schilling:The biotech sector revolves around two things, FDA decisions and EPS announcements. In this article I wanted to focus on two companies who have announced significant drug-related developments in the last 24 hours.

The Burrill Report submits: June has been heating up for life sciences companies replenishing their coffers. Only three weeks after announcing positive mid-stage data on its endometriosis-related pain therapeutic elagolix, Neurocrine Biosciences (NBIX) lined up a partner in Abbott Laboratories (ABT) to help develop and commercialize the compound.

By Markus Aarnio:Synta Pharmaceuticals (SNTA) is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases.

By Markus Aarnio:United Therapeutics Corporation (UTHR) is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening cardiovascular and infectious diseases and cancer. The company's lead product, Remodulin, is approved in the U.S.

By Bret Jensen:Regular readers of my columns know that my philosophy on small drug & biotech stocks is to take a "shotgun" approach. Lots of small positions in promising equities within the space instead of bigger core positions like I prefer in other sectors. One promising drug stock has popped up on my radar due to some recent positive analyst comments and it looks worthy of a small speculative investment.

ByPropThink: By Jake King

By Brian L. Wilson:Astex Pharmaceuticals (ASTX) is a pharmaceutical company that is in the process of developing a plethora of clinical-stage oncology drugs.